HXR9
HXR9 is a cell-permeable peptide and a competitive antagonist of HOX/PBX interaction. HXR9 antagonizes the interaction between HOX and a second transcrip-tion factor (PBX), which binds to HOX proteins in paralogue groups1 to 8. HXR9 selectively decreases cell proliferation and promotes apoptosis in cells with a high level of expression of the HOXA/PBX3 genes, such as MLL-rearranged leukemic cells.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 917953-08-3
- Fòrmula: C119H193N53O20S
- Peso molecular:2718.21
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
HXR9 (60μM; 4 hours) blocks the interaction between PBX and HOX[1].
HXR9 (60μM; 2 hours) triggers apoptosis in B16 and primary melanoma cells[1].
HXR9 (60μM; 2 hours) causes specific transcriptional changes[1].
HXR9 (B16 cells) shows antiproliferative activity with an IC50 of 20μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:murine B16melanoma cells
-
Concentration:60 μM
-
Incubation Time:4 hours
-
Result:Blocked the binding of HOXD9 to PBX.
-
Cell Line:B16 cells
-
Concentration:60 μM
-
Incubation Time:2 hours
-
Result:A significant proportion of cells were in late phases of apoptosis.
-
Cell Line:B16F10cells
-
Concentration:60 μM
-
Incubation Time:2 hours
-
Result:Fos, Jun, Dusp1, and Atf1，were allsignificantly up-regulate.
HXR9 (Initial dose of 100 mg/kg (subsequent dosing of 10 mg/kg twice weekly); Intraperitoneal; twice weekly for 18 days) blocks A549 tumour growth in vivo[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57black/6 mice (bearing B16 cells)
-
Dosage:10 mg/kg
-
Administration:I.v. via the tail vein; twice weekly (~30 days)
-
Result:Tumors showed a significant degree of growth retardation.
-
Animal Model:Athymic nude mice (bearing A549 cells)
-
Dosage:Initial dose of 100 mg/kg (subsequent dosing of 10 mg/kg twice weekly)
-
Administration:Intraperitoneal; twice weekly for 18 days
-
Result:The tumours of HXR9-treated mice were considerably smaller than those of the control groups.
Chemical Information
-
No. CAS 917953-08-3
-
Peso molecular 2718.21
-
Fòrmula C119H193N53O20S
-
Sequence
Trp-Tyr-Pro-Trp-Met-Lys-Lys-His-His-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg
-
Sequence Shortening
WYPWMKKHHRRRRRRRRR
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Morgan R, et al. Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma. Cancer Res. 2007;67(12):5806-5813. [Content Brief]
[2]. Li Z, et al. PBX3 is an important cofactor of HOXA9 in leukemogenesis. Blood. 2013;121(8):1422-1431. [Content Brief]
[3]. Plowright L, et al. HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer). Br J Cancer. 2009;100(3):470-475. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
HXR9 Related Classifications
HY-P3245 Related Classifications
Powered by Bioz